Triple Vascular Screening Reduces Mortality for Older Men
By MedImaging International staff writers Posted on 13 Sep 2017 |
The results of a large screening trial have shown that the overall mortality of men aged between 65 and 74 could be reduced by 7%, by using combined Peripheral Artery Disease (PAD), hypertension, and Abdominal Aortic Aneurysm (AAA) screening, compared with no screening at all.
The goal of the randomized controlled trial was to examine the effect, and cost-effectiveness of the combined screening, compared to current cardiovascular screening of AAA disease alone. Combined screening consisted of Doppler-based ankle brachial index for PAD, and abdominal ultrasound for AAA. The primary outcome was all-cause mortality, while the secondary outcomes included cause-specific mortality, renal failure, cancer, diabetes, and other factors.
The results of the Viborg Vascular (VIVA) Trial that included 50,168 men from the center of Denmark, were published in the August 28, 2017, issue of the journal The Lancet, by researchers from the Odense University Hospital (Odense, Denmark), and Aarhus University (Aarhus, Denmark).
The results indicated that combined vascular AAA, PAD and hypertension screening resulted in an observed reduction of mortality risk in the study population without serious negative side effects. The researchers recommend that the combined screening method could be used as a good and cost-effective mortality prevention strategy for older men.
Chadi Ayoub, MBBS, and M. Hassan Murad, MD, said, "The VIVA trial presents thought-provoking findings. However, implementation of this triple screening intervention requires more proof than presented in this study. The 10 criteria developed in the 1960s by WHO13 remain a valid framework for establishing whether screening should be implemented or scarce resources should be directed at individuals with increased risk of morbidity and mortality."
Related Links:
Odense University Hospital
Aarhus University
The goal of the randomized controlled trial was to examine the effect, and cost-effectiveness of the combined screening, compared to current cardiovascular screening of AAA disease alone. Combined screening consisted of Doppler-based ankle brachial index for PAD, and abdominal ultrasound for AAA. The primary outcome was all-cause mortality, while the secondary outcomes included cause-specific mortality, renal failure, cancer, diabetes, and other factors.
The results of the Viborg Vascular (VIVA) Trial that included 50,168 men from the center of Denmark, were published in the August 28, 2017, issue of the journal The Lancet, by researchers from the Odense University Hospital (Odense, Denmark), and Aarhus University (Aarhus, Denmark).
The results indicated that combined vascular AAA, PAD and hypertension screening resulted in an observed reduction of mortality risk in the study population without serious negative side effects. The researchers recommend that the combined screening method could be used as a good and cost-effective mortality prevention strategy for older men.
Chadi Ayoub, MBBS, and M. Hassan Murad, MD, said, "The VIVA trial presents thought-provoking findings. However, implementation of this triple screening intervention requires more proof than presented in this study. The 10 criteria developed in the 1960s by WHO13 remain a valid framework for establishing whether screening should be implemented or scarce resources should be directed at individuals with increased risk of morbidity and mortality."
Related Links:
Odense University Hospital
Aarhus University
Latest MRI News
- World's First Sensor Detects Errors in MRI Scans Using Laser Light and Gas
- Diamond Dust Could Offer New Contrast Agent Option for Future MRI Scans
- Combining MRI with PSA Testing Improves Clinical Outcomes for Prostate Cancer Patients
- PET/MRI Improves Diagnostic Accuracy for Prostate Cancer Patients
- Next Generation MR-Guided Focused Ultrasound Ushers In Future of Incisionless Neurosurgery
- Two-Part MRI Scan Detects Prostate Cancer More Quickly without Compromising Diagnostic Quality
- World’s Most Powerful MRI Machine Images Living Brain with Unrivaled Clarity
- New Whole-Body Imaging Technology Makes It Possible to View Inflammation on MRI Scan
- Combining Prostate MRI with Blood Test Can Avoid Unnecessary Prostate Biopsies
- New Treatment Combines MRI and Ultrasound to Control Prostate Cancer without Serious Side Effects
- MRI Improves Diagnosis and Treatment of Prostate Cancer
- Combined PET-MRI Scan Improves Treatment for Early Breast Cancer Patients
- 4D MRI Could Improve Clinical Assessment of Heart Blood Flow Abnormalities
- MRI-Guided Focused Ultrasound Therapy Shows Promise in Treating Prostate Cancer
- AI-Based MRI Tool Outperforms Current Brain Tumor Diagnosis Methods
- DW-MRI Lights up Small Ovarian Lesions like Light Bulbs